

# Dopamine Handbook

*Edited by*

**LESLIE L. IVERSEN, PhD, FRS**

*Professor of Pharmacology  
University of Oxford  
Oxford, UK*

**SUSAN D. IVERSEN, PhD**

*Department of Experimental Psychology  
University of Oxford  
Oxford, UK*

**STEPHEN B. DUNNETT, PhD**

*School of Biosciences  
Cardiff University  
Cardiff, UK*

**ANDERS BJÖRKLUND, MD, PhD**

*Wallenberg Neuroscience Center  
Division of Neurobiology  
Lund University  
Lund, Sweden*

**OXFORD**

UNIVERSITY PRESS

2010

# Contents

*Contributors* xi

- 1 **Overview: A personal view of the dopamine neuron in historical perspective** 3  
*Floyd E. Bloom*
- 2 **Neuroanatomy** 9
  - 2.1. Functional Neuroanatomy of Dopamine in the Striatum 11  
*Charles R. Gerfen*
  - 2.2. Functional Implications of Dopamine D2 Receptor Localization in Relation to Glutamate Neurons 22  
*Susan R. Sesack*
  - 2.3. Convergence of Limbic, Cognitive, and Motor Cortico-Striatal Circuits with Dopamine Pathways in Primate Brain 38  
*Suzanne N. Haber*
  - 2.4. The Relationship between Dopaminergic Axons and Glutamatergic Synapses in the Striatum: Structural Considerations 49  
*Jonathan Moss and J. Paul Bolam*
- 3 **Molecular pharmacology** 61
  - 3.1. Molecular Pharmacology of the Dopamine Receptors 63  
*Michele L. Rankin, Lisa A. Hazelwood, R. Benjamin Free, Yoon Namkung, Elizabeth B. Rex, Rebecca A. Roof, and David R. Sibley*
  - 3.2. Role of Dopamine Transporters in Neuronal Homeostasis 88  
*Marc G. Caron and Raul R. Gainetdinov*
  - 3.3. Intracellular Dopamine Signaling 100  
*Gilberto Fisone*
  - 3.4. Ion Channels and Regulation of Dopamine Neuron Activity 118  
*Birgit Liss and Jochen Roeper*
- 4 **Genes in development** 139
  - 4.1. Genetic Control of Meso-diencephalic Dopaminergic Neuron Development in Rodents 141  
*Wolfgang Wurst and Nilima Prakash*
  - 4.2. Factors Shaping Later Stages of Dopamine Neuron Development 160  
*Robert E. Burke*
  - 4.3. Postnatal Maturation of Dopamine Actions in the Prefrontal Cortex 177  
*Patricio O'Donnell and Kuei Y. Tseng*

- 4.4. Genetic Dissection of Dopamine-Mediated Prefrontal-Striatal Mechanisms and Its Relationship to Schizophrenia 187  
*Hao-Yang Tan and Daniel R. Weinberger*
- 5 Dopamine in prefrontal cortex and cognition 201**
- 5.1. From Behavior to Cognition: Functions of Mesostriatal, Mesolimbic, and Mesocortical Dopamine Systems 203  
*Trevor W. Robbins*
- 5.2. Contributions of Mesocorticolimbic Dopamine to Cognition and Executive Function 215  
*Stan B. Floresco*
- 5.3. Dopamine's Influence on Prefrontal Cortical Cognition: Actions and Circuits in Behaving Primates 230  
*Amy F.T. Arnsten, Susheel Vijayraghavan, Min Wang, Nao J. Gamo, and Constantinos D. Paspalas*
- 5.4. Dopaminergic Modulation of Flexible Cognitive Control in Humans 249  
*Roshan Cools and Mark D'Esposito*
- 5.5. Neurocomputational Analysis of Dopamine Function 261  
*Daniel Durstewitz*
- 6 Striatum and midbrain—motor and motivational functions 277**
- 6.1. Dopamine and Motor Function in Rat and Mouse Models of Parkinson's Disease 279  
*Timothy Schallert and Sheila M. Fleming*
- 6.2. Involvement of Nucleus Accumbens Dopamine in Behavioral Activation and Effort-Related Functions 286  
*John D. Salamone*
- 6.3. Functional Heterogeneity in Striatal Subregions and Neurotransmitter Systems: Implications for Understanding the Neural Substrates Underlying Appetitive Motivation and Learning 301  
*Brian A. Baldo and Matthew E. Andrzejewski*
- 6.4. Behavioral Functions of Dopamine Neurons 316  
*Philippe N. Tobler*
- 7 Plasticity of forebrain dopamine systems 331**
- 7.1. Dynamic Templates for Neuroplasticity in the Striatum 333  
*Ann M. Graybiel*
- 7.2. Dopamine and Synaptic Plasticity in Mesolimbic Circuits 339  
*F. Woodward Hopf, Antonello Bonci, and Robert C. Malenka*
- 7.3. Dopaminergic Modulation of Striatal Glutamatergic Signaling in Health and Parkinson's Disease 349  
*D. James Surmeier, Michelle Day, Tracy S. Gertler, C. Savio Chan, and Weixing Shen*
- 8 Dopamine mechanisms in addiction 369**
- 8.1. The Role of Dopamine in the Motivational Vulnerability to Addiction 371  
*George F. Koob and Michel Le Moal*
- 8.2. Dopaminergic Mechanisms in Drug-Seeking Habits and the Vulnerability to Drug Addiction 389  
*Barry J. Everitt, David Belin, Jeffrey W. Dalley, and Trevor W. Robbins*
- 8.3. Imaging Dopamine's Role in Drug Abuse and Addiction 407  
*Nora D. Volkow, Joanna S. Fowler, Gene-Jack Wang, Frank Telang, and Ruben Baler*

- 9 Parkinson's disease 419**
- 9.1. Exploring the Myths about Parkinson's Disease 421  
*Yves Agid and Andreas Hartmann*
  - 9.2. Pathophysiology of L-DOPA-Induced Dyskinesia in Parkinson's Disease 434  
*M. Angela Cenci*
  - 9.3. Progression of Parkinson's Disease Revealed by Imaging Studies 445  
*David J. Brooks*
  - 9.4. Transplantation of Dopamine Neurons: Extent and Mechanisms of Functional Recovery in Rodent Models of Parkinson's Disease 454  
*Stephen B. Dunnett and Anders Björklund*
  - 9.5. Clinical Experiences with Dopamine Neuron Replacement in Parkinson's Disease: What Is the Future? 478  
*Olle Lindvall*
  - 9.6. Novel Gene-Based Therapeutics Targeting the Dopaminergic System in Parkinson's Disease 489  
*Deniz Kirik, Tomas Björklund, Shilpa Ramaswamy, and Jeffrey H. Kordower*
  - 9.7. Neuroprotective Strategies in Parkinson's Disease 498  
*C. Warren Olanow*
- 10 Schizophrenia and other psychiatric illnesses 509**
- 10.1. Dopamine Dysfunction in Schizophrenia 511  
*Anissa Abi-Dargham, Mark Slifstein, Larry Kegeles, and Marc Laruelle*
  - 10.2. Neuropharmacological Profiles of Antipsychotic Drugs 520  
*Bryan L. Roth and Sarah C. Rogan*
  - 10.3. How Antipsychotics Work: Linking Receptors to Response 540  
*Nathalie Ginovart and Shitij Kapur*
  - 10.4. Dopamine Dysfunction in Schizophrenia: From Genetic Susceptibility to Cognitive Impairment 558  
*Heike Tost, Shabnam Hakimi and Andreas Meyer-Lindenberg*
  - 10.5. The Role of Dopamine in the Pathophysiology and Treatment of Major Depressive Disorder 572  
*Boadie W. Dunlop and Charles B. Nemeroff*
  - 10.6. Dopamine Modulation of Forebrain Pathways and the Pathophysiology of Psychiatric Disorders 590  
*Anthony A. Grace*
- Index 599*

Dopamine is generally titrated in increments of 2 - 5  $\mu\text{g}/\text{kg}/\text{min}$  q 2-5 min to effect. Pediatric. Same as adult. Special Notes. When administering a dopamine infusion, an infusion pump should be used (ideal), or an in-line Buretrol (2nd best), or a minidrip (last choice). Fill Buretrol with 50 ml of the dopamine solution from the pre-mixed bag. Then close the Buretrol line off to the bag. Dopamine is most often used in the prehospital setting for post-arrest hypotension. Dopamine Handbook. January 2010.

DOI:10.1093/acprof:oso/9780195373035.001.0001. Abstract. The discovery of dopamine in 1957-8 was one of the seminal events in the development of modern neuroscience, and has been extremely important for the development of modern therapies of neurological and psychiatric disorders. Read PDF Dopamine Handbook. modern books. Though they are not so known publicly, the books range from romance, historical or mystery to science fiction that can be of your interest. Dopamine Handbook To this end, radioreceptor and functional studies of these three compounds were conducted at each of the known molecular isoforms of the dopamine receptors in several transfection systems Interactions of the Novel Antipsychotic Aripiprazole. (OPC-14597) with Dopamine and Serotonin Receptor.